

John Wainwright PhD Joins MIVI Neuroscience as Vice President, R&D

PRESS RELEASE **UPDATED: AUG 18, 2021**

EDEN PRAIRIE, Minn., August 18, 2021 (NewsWire.com) - MIVI Neuroscience today announced that John Wainwright, PhD has joined the Company as Vice President, Research and Development. In this role, John will lead the R&D team and participate in the development and execution of the Company's key strategic initiatives.

Most recently, John served as Director of Research, Development and Technology at Medtronic/Covidien Neurovascular where he spent over ten years in the development and management of multiple neurovascular devices and delivery systems. Prior to Medtronic, John's experience included engineering and research roles in both industry and academia, including ViaDerm, the University of Pittsburgh and Cordis. John earned his BS in Chemical Engineering and ME in Biomedical Engineering from the University of Florida, Gainesville and his Ph.D. in Bioengineering from the University of Pittsburgh. Over his career, John has published over 51 patents/applications and scientific publications.

"John is an outstanding addition to the MIVI Team as he brings a unique blend of creative innovation and execution skills to our research and development effort," said Bob Colloton, CEO of MIVI Neuroscience. "John is an experienced, well-regarded senior leader in the neurovascular therapy space and we are excited to benefit from his ability to further develop and expand our unique product portfolio."

"MIVI is positioned to continue to help neurointerventionalists around the world improve stroke therapy outcomes," commented John. "I am excited to join the MIVI team and build on the Company's solid foundation of patient commitment and product innovation."

About MIVI Neuroscience

MIVI Neuroscience, Inc. is focused on developing and commercializing superior clinical solutions for neurointerventional procedures. MIVI's innovative product portfolio provides physicians with unique devices designed to improve patient outcomes in these procedures by reducing complications, shortening procedure times and expanding treatment to more patients. More information about MIVI can be found on the website www.mivineuro.com.

Source: MIVI Neuroscience Inc
